Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Large US trial supports silver diamine fluoride for severe early childhood caries

3

Aug 2026

Large US trial supports silver diamine fluoride for severe early childhood caries

A phase 3 randomized trial of 830 young children with severe early childhood caries found that 38% silver diamine fluoride arrested 54.0% of eligible cavitated dentin lesions at six months, compared with 22.5% after placebo. The noninvasive treatment showed clinically meaningful efficacy, but about half of the lesions remained active, supporting close monitoring and additional preventive care.

First consensus guidelines outline GLP-1 medication use during pregnancy

3

Aug 2026

First consensus guidelines outline GLP-1 medication use during pregnancy

As the use of GLP-1 and other incretin-based medications for obesity continues to grow worldwide, researchers at Marshall University have contributed to an international effort to address one of medicine's most pressing unanswered questions: How should these medications be used by women before, during and after pregnancy?

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.